Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects

References

• Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., Schneider, R. L. (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 study group. Diabetes Care 23:1605–1611.
   PubMed Web of Science ®Google Scholar
• Baba, S. (2001). Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 17:166–189.
   PubMed Web of Science ®Google Scholar
• Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L., et al. (2003). Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364–1370.
   PubMed Web of Science ®Google Scholar
• Belle, D. J., Singh, H. (2008). Genetic factors in drug metabolism. Am Fam Physician 77:1553–1560.
   PubMed Web of Science ®Google Scholar
• Budde, K., Neumayer, H. H., Fritsche, L., Sulowicz, W., Stompor, T., Eckland D. (2003). The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368–374.
   PubMed Web of Science ®Google Scholar
• Despres, J. P., Lamarche, B., Mauriege, P., Cantin, B., Dagenais, G. R., Moorjani, S., et al. (1996). Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957.
   PubMed Web of Science ®Google Scholar
• Dormandy, J. A., Charbonnel, B., Eckland, D. J. A., Erdmann, E., Massi- Benedetti, M., Moules, I. K, et al. (2005). Secondary prevention of macro vascular events in patients with type 2 diabetes in the PROactive study (Prospective pioglitazone clinical trial in macroVascular events): a randomized controlled trial. Lancet 366:1279–1289.
   PubMed Web of Science ®Google Scholar
• Eckland, D. A., Danhof, M. (2000). Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108 (Suppl 2):S234–S242.
   Google Scholar
• Erdmann, E., Dormandy, J. A., Charbonnel, B., Massi-Benedetti, M., Moules, I. K., Skene, A. M. (2007). The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 49:1772–1780.
   PubMed Web of Science ®Google Scholar
• Flockhart, D. A., Desta, Z. (2009). Pharmacogenetics of drug metabolism. In: Robertson, D., Williams, G. H. (Eds.), Clinical and translational science: principles of human research (pp. 301–317). San Diego, California, USA: Elsevier.
   Google Scholar
• Gillies, P. S., Dunn, C. J. (2000). Pioglitazone. Drugs 60:333–343.
   PubMed Web of Science ®Google Scholar
• Hanefeld, M. (2001). Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 121:19–25.
   PubMedGoogle Scholar
• Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., et al. (2007). Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein. J Am Coll Cardiol 49:290–297.
   PubMed Web of Science ®Google Scholar
• Li, J. (2006). Peroxisome proliferator-activated receptor (PPAR) agonists for type 2 diabetes. In: Johnson, D. S., Li, J. J. (Eds.), The art of drug synthesis (pp. 115–127). Hoboken, New Jersey, USA: John Wiley and Sons.
   Google Scholar
• Madan, P. (2005). Effect of thiazolidinediones on lipid profile. CMAJ 173:344–345.
   PubMed Web of Science ®Google Scholar
• Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., et al. (2001). Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719.
   PubMed Web of Science ®Google Scholar
• Prentis, R. A., Lis, Y., Walker, S. R. (1988). Pharmaceutical innovation by seven UK-owned pharmaceutical companies (1964–1985). Br J Clin Pharmacol 25:387–396.
   PubMed Web of Science ®Google Scholar
• Reed, M. J., Meszaros, K., Entes, L. J., Claypool, M. D., Pinkett, J. G., Brignetti, D., et al. (1999). Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia 42:102–106.
   PubMed Web of Science ®Google Scholar
• Ripsin, C. M., Kang, H., Urban, R. J. (2009). Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 79:29–36.
   PubMed Web of Science ®Google Scholar
• Stevenson, R. W., McPherson, R. K., Genereux, B. E., Danbury, B. H., Kreutter, D. K. (1991). Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism 40:1268–1274.
   PubMed Web of Science ®Google Scholar
• Torii, H. K., Yoshida, T., Tsukamoto, T., Tanayama, S., (1984). Disposition in rats and dogs of ciglitazone, a new antidiabetic agent. Xenobiotica 14:259–268.
   PubMed Web of Science ®Google Scholar
• Tsuchida, E., Abe, K. (1982). Interactions between macromolecules in solutions and intermolecular complexes. In: Cantow, H. W., Asta, G. D., DuSek, K., Ferry, J. D., Fujita, H., Gordon, M., et al. (Eds.), Advances in polymer science (vol. 45, pp. 1–119). New York: Springer-Verlag.
   Google Scholar
• Uwaifo, G. I., Ratner, R. E. (2003). The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med 115 (Suppl. 8A):12S–19S
   PubMedGoogle Scholar
• Walker, D. K. (2004). The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 58:6601–6608.
   Google Scholar
• Waugh, J., Keating, G. M., Plosker, G. L., Easthope, S., Robinson, D. L. (2006). Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 66:85–109.
   PubMed Web of Science ®Google Scholar
• Wild, S., Bchir, M. B., Roglic, G., Green, A., Sicree, R., King, H. (2004). Global prevalence of diabetes. Diabetes Care 27: 1047–1053.
   PubMed Web of Science ®Google Scholar
• Wittayalertpanya, S., Chompootaweep, S., Thaworn, N. (2006). The pharmacokinetics of pioglitazone in Thai healthy subjects. J Med Assoc Thai 89:2116–2122.
   PubMedGoogle Scholar
• Zhang H, Wang, X. Q., Zhang, X., Zhang, Q., Yin, Q., Li, K. X. (2004). Study on bioequivalence of pioglitazone hydrochloride tablets in healthy Chinese volunteers. Asian J Drug Metab Pharmacokinet 4:119–122.
   Google Scholar